SOPHiA GENETICS offers the SOPHiA DDM platform, which analyzes complex genomic and multimodal data to generate real‑time, actionable insights for hospitals, laboratories, and biopharma institutions. The platform is seeing global clinical adoption, with 463 core genomics customers and recent partnerships including Mayo Clinic going live for hereditary cancer and rare disease testing. In Q1 2024 the company reported $15.8 million in revenue, a 13% year‑over‑year increase, and operating losses of $18.8 million. Management reiterated full‑year 2024 guidance of 25%–30% revenue growth, an adjusted gross margin between 72.5% and 72.7%, and an adjusted operating loss of $45 million to $50 million. The company has arranged financing to support its growth initiatives and operations while continuing to expand access to data‑driven medicine. SOPHiA GENETICS states its mission is to use AI to deliver care for patients with cancer and rare disorders worldwide. SOPHiA GENETICS combines machine learning applied to medical imaging with genomic sequencing to generate a more holistic view of disease and improve care coordination. Its technology integrates multiple sources of medical data to surface novel insights about how diseases spread in the body. The Boston- and Lausanne, Switzerland-based company says its platform is used by more than 1,000 healthcare institutions and has analyzed 600,000 genomic profiles. The firm plans to use new funding to expand its footprint in the U.S. and Asian markets. Leadership changes — including adding former Agilent CFO Didier Hirsch to the board and creating an audit committee — suggest preparation for a potential public offering. The company emphasizes better patient care as its primary goal. Sophia Genetics develops SOPHiA AI, a universal platform that enables healthcare professionals to analyze complex genomic and radiomic data for oncology and hereditary disorders. Led by CEO and founder Dr. Jurgi Camblong, the company combines life sciences and medical expertise with advanced data computing and mathematical capabilities. Sophia Genetics is based in Lausanne, Switzerland, and Boston, MA. Its platform is utilized by more than 850 hospitals across 77 countries and has supported the diagnosis of over 300,000 patients. The company closed a $77M funding round and has now raised a total of $140M. It plans to use the funds to accelerate the reach of its data-driven medicine solutions and add talent to reinforce its presence in the US. Sophia Genetics operates a SaaS big-data analytics platform that aggregates clinician-fed genomic data and applies statistical inference and machine-learning algorithms to improve DNA-sequencing diagnostic accuracy. The platform ingests raw FASTQ data, has been validated on over 340 different sequencers, and has benchmarked samples from more than 10,000 patients and 500,000 unique variants. Hospitals connect and share annotated results so the AI improves as the user base grows — the company says it is adding about 10 new hospitals per month and currently works with over 350 hospitals. Accuracy has improved over time (from ~85% to ~98% in successive 10k-patient cohorts) with reported sensitivity between 99.9%–100% and specificity between 99%–100%. Sophia charges hospitals on a per-analysis, on-demand basis. With cheaper sequencing and richer datasets the company plans to expand analytic layers (for example combining imaging with molecular data) and to push deeper into oncology-case management and multi-modal predictive analyses. The new funding is intended to support global deployment and ramp commercial activity beyond Europe into Latin America, AsiaPac, Canada and the U.S. Sophia Genetics offers the Sophia DDM™ analytics platform, which hosts machine-learning algorithms and a large clinical genomics community to analyze genetic data for cancers and inherited conditions. The company supports more than 100 healthcare institutions across 20 countries, including Oxford University Hospital, Hospices Civils de Lyon, Vall d’Hebron Hospital and Cologne University Hospital. Led by CEO and co-founder Jurgi Camblong, the team comprises about 60 employees, two thirds of whom hold PhDs in genomics, bioinformatics, computational and data protection. Sophia leverages advanced analytics to help more accurately and quickly diagnose thousands of patients. The company plans to use new funding to continue market expansion and broaden its range of genomic tests. The firm has previously received backing from Mike Lynch, founder of Invoke Capital.

Total raised

$296M

Funding rounds

6

Latest round

Debt Financing

Latest activity

May 2024